Abstract 153P
Background
T cell immunoglobulin and mucin domain molecule 3 (Tim-3) is of overexpression in immunotherapy-resistant tumors. This single-arm, two-cohort, phase 2 study (NCT05563480) aimed to explore the efficacy and safety of TQB2618, a novel monoclonal antibody agent blockading Tim-3, plus PD-1 blockade penpulimab in subsequent-line treatment (cohort 1) of immunotherapy-resistant R/M NPC or in the first line by incorporating into chemotherapy (cohort 2) in treatment-naïve R/M NPC. Here, we report the preliminary results of cohort 1.
Methods
Eligible pts were diagnosed with histologically confirmed R/M NPC with ≥ 1 measurable lesion and had progressed on or after ≥ 1 line of platinum-based chemotherapy and PD-(L)1 immunotherapy. Pts were given penpulimab 200 mg and TQB2618 intravenously once per 3 weeks till disease progression or intolerance. Two TQB2618 dose levels of 1200 mg and 1500 mg were escalated initially according to the 3+3 design in a safety lead-in phase to determine the recommended dose in expansion phase. The primary aim of cohort 1 is to determine dose limiting toxicity (DLT) and tumor response.
Results
Between November 2022 and September 2023, 17 pts were enrolled (median [range] age, 49 [33–62] years; 41.2% women). The median previous treatment lines were 2 (range: 1–5). All pts developed metastasis and 7 (41.2%) were found liver lesions. The DLT was not observed, and 1500 mg was recommended for TQB2618. All pts received safety evaluation and 13 (76.5%) occurred at least one AE. The most common AEs were hypothyroidism (41.2%) and increased aspartate aminotransferase (23.5%). AEs of ≥ grade 3 or serious AEs were not observed. Seven pts had target lesions shrink although no one reached partial response. Nine pts obtained stable disease lasting for at least 4 weeks, given a disease control rate of 52.9%. The median PFS was 1.6 mo (95% CI, 0.0–3.2); 3 mo- and 6 mo-PFS was 27.3% and 18.2%, respectively. One pt was still on treatment after a follow-up for 14 months.
Conclusions
This novel dual-drug immunotherapy showed favorable safety profile, but the activity was limited in immunotherapy-resistant R/M NPC.
Clinical trial identification
NCT05563480.
Legal entity responsible for the study
The authors.
Funding
Chia Tai TianQing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract